According to a recent study conducted by US researchers, injections of a new type of botulinum toxin called Reloxin, which is well tolerated by patients, may help in the reduction of wrinkles. This study was led by Ronald Moy, M.D., Moy-Fincher Medical Group, Los Angeles, along with colleagues. However, skeptics are not convinced by new study, which was funded by the drug's maker, Medicis Pharmaceutical Corp. The results have been published in the March/April issue of the Archives of Facial Plastic Surgery.

Study Highlights
a. 1,200 patients were treated with injections of Reloxin (Clostridium botulinum toxin type A-hemagglutinin complex) in five sites in the forehead.
b. Patients had to keep diaries noting down the effects of the treatment.
c. They were surveyed a week to 10 days after treatment.
d. They were also reexamined after 2 weeks and 30 days and then again each month after treatment.
e. It was seen that out of the 1,052 patients who completed the 13-month study, 880 patients complained of 2,838 adverse events.
f. Of these, 28 per cent is thought to be related to the treatment.
g. Adverse effects included problems at the injection site, headache and eye problems including ptosis, a drooping of the eyelid or brow.
h. One patient withdrew from the study after suffering side effects of the drug.
i. Patients saw results within a day after treatment.
j. After a week, about 95 per cent of the patients responded positively to the medication.
k. After 30 days, almost 91 per cent of the patients reported a response to the medication.
l. The safety profile seemed to be similar to Botox but researchers noticed more drooping in Reloxin than is seen with Botox.
m. In this study, researchers did not address the issue of volume of distribution or technical differences between Reloxin and Botox.

Highlights of Reloxin
A, This medication prevents facial muscles from contracting.
b. The results last for several months.
c. It is approved for use in 23 countries outside the United States to smooth wrinkles.
d. It has been used outside the United States for more than 15 years to treat neurological disorders.
e. The US Food and Drug Administration is yet to give its approval for the drug.
f. Reloxin is set to be priced less than Botox.

Differences between Botox and Reloxin
a. Reloxin has less protein in its formula than botox.
b. Reloxin contains fewer antigens than botox, which cause the drug to break down more quickly.
c. Reloxin also defuses more in the tissue than Botox.
d. However, according to results of some early trials Botox lasts longer than Reloxin.